MHRA unveils strategy for regulating AI technologies

Home/Policies & Legislation | Posted 22/05/2024 post-comment0 Post your comment

In April 2024, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) published a policy paper on its strategic approach to artificial intelligence (AI) [1]. It summarises the MHRA’s view on the UK government’s white paper on AI regulation published in 2023 [2] and is the agency’s response to the Secretary of State letter of 1 February 2024 [3].

23 AA011020

The policy paper provides an update on the MHRA's use of AI as a regulator of AI products, as a public service organization delivering time-critical decisions and as an organization making evidence-based decisions that impact public safety.

In the policy paper, MHRA outline strategy on how incorporating AI into the MHRA’s regulatory processes could help the agency focus on key priorities such as innovation. MHRA highlights that AI offers ‘improved efficiencies’, enabling patients in the UK to safely access medical products earlier. In addition, as a regulatory authority, the processes and protocols required to assess submissions and examine data should ‘evolve in line with innovative AI’.

With this in mind, MHRA highlighted that they should be established as:

  • a regulator of AI products
  • a public service organization delivering time-critical decisions
  • an organization making evidence-based decisions that impact on public and patient safety, where that evidence is often supplied by third parties.

In addition, MHRA stress that ‘AI is likely to be integral to ensuring effective product regulation and patient safety, and therefore measuring and understanding its impact is essential for the agency to remain an effective and innovative regulator’. 

In summary, MHRA aims to embrace the use of AI in regulatory processes and post acceptance monitoring. In a statement, Dr Laura Squire, Chief Quality and Access Officer at the MHRA, said, ‘AI offers us the opportunity to improve the efficiency of the services we provide across all our regulatory functions from regulatory science, through enabling safe access for medicines and medical devices, to post market surveillance and enforcement’.

Related articles
Latin America's biosimilars market: regulatory, institutional, and technological aspects

UK updates guidance to allow biosimilars interchangeability

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Bio-Thera y SteinCares firman acuerdo para comercializar dos biosimilares en LATAM

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Bio-Thera y SteinCares firman acuerdo para comercializar dos biosimilares en LATAM

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 


1. Government UK. Impact of AI on the regulation of medical products [homepage on the Internet]. [cited 2024 May 22]. Available from: https 
2. Government UK. A pro-innovation approach to AI regulation: government response [homepage on the Internet]. [cited 2024 May 22]. Available from:
3. Government UK.  Letter from DSIT and DHSC Secretaries of State to the Medicines and Healthcare products Regulatory Agency - HTML [homepage on the Internet]. [cited 2024 May 22]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2024 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Panama embraces international pharmacovigilance standards
Pharmacovigilance V13F21
Home/Policies & Legislation Posted 09/07/2024
FDA proposal to remove biosimilar interchangeability status in FY25
01 AA007239
Home/Policies & Legislation Posted 12/06/2024
Regulatory Certainty Strategy for biosimilars launched in Mexico
Home/Policies & Legislation Posted 09/04/2024
Strategic plans of ANVISA and COFEPRIS to advance health regulation
11 AA010165
Home/Policies & Legislation Posted 11/03/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010